Evidence map›Paper›PMID 40510155›Full record

ArticleFrontiers in oncology2025

Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting.

Jian Zhang, Yuxin Mu, Hui Zhang, Chao Deng, Jiao Yang, Lu Gan, Qingmo Yang, Xuefeng Xu, Wanping Liang, Xiaowei Qi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jian Zhang *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yuxin Mu *Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Hui ZhangDepartment of Breast Surgery, Fujian Provincial Hospital, Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.
Chao DengBreast Center (Department of Internal Medicine), Chongqing University Three Gorges Hospital, Chongqing, China.
Jiao YangDepartment of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Lu GanDepartmen of Medical Oncology, The First Hospital of Chongqing Medical University Affiliated Hospital, Chongqing, China.
Qingmo YangDepartment of Breast Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Xuefeng XuDepartment of Breast Surgery, Zhangjiakou First Hospital, Zhangjiakou, China.
Wanping LiangDepartment of Breast Surgery, The First Affiliated Hospital of Hebei Northern University, Zhangjiakou, China.
Xiaowei QiDepartment of Thyroid Breast Surgery, Southwest Hospital of Army Medical University, Chongqing, China.
Liang XuDepartment of Medical Oncology, Anyang Cancer Hospital, Anyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Inetetamab is a novel recombinant humanized anti-Human epidermal growth factor receptor 2 (HER2) monoclonal antibody. This real-world retrospective study assessed the efficacy and safety of inetetamab-containing regimens in first-line/second-line treatment of HER2-positive metastatic breast cancer (MBC). Methods: This study retrospectively recruited HER2-positive MBC patients who received inetetamab- containing regimens from June 2020 to May 2023. The outcomes included progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Results: A total of 329 patients were enrolled and included in the efficacy analysis. The most frequently used treatment strategy was contained inetetamab plus pyrotinib (205/329, 62.3%). Patients treated with first-line regimens benefited the most, with a median PFS of 15.0 versus (vs.) 10.0 months (first-line- vs. second-line inetetamab plus pyrotinib, Conclusions: Following the first- and second-line of treatment, inetetamab- containing combinations demonstrated promising clinical activity and a manageable safety profile in patients with HER2-positive MBC, especially in the first-line treatment.

Indexed as

chemotherapyfirst-line/second-line therapyHER2-positive metastatic breast cancerinetetamab-containing regimenspertuzumabpyrotinib

Identifiers

PMID40510155
PMCPMC12158944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.